Dr Marcus Flather, consultant cardiologist at the Royal Brompton and director of its clinical trials and evaluation unit said hospitals needed to boost the use of these effective treatments.
The Visudyne dye, which is manufactured by drug company CIBA UK, was approved by the European Medicines Evaluation Agency four weeks ago after being tested in two 12-month clinical trials.
The class labeling is based on FDA evaluation of all statin labels, entry of new interacting drugs on the market, and a review of clinical data and post marketing reports.